Methysergide-induced valvular heart disease: a report of 2 cases.
Methysergide is a serotonin antagonist and is used as a long-term prophylactic treatment for migraine. Although many patients experience adequate control of migraine episodes, methysergide has been reported to cause retroperitoneal and pleuropulmonary fibrosis. Cardiovascular side effects mainly in the form of valvular fibrosis have been less recognized. We report 2 cases of methysergide-related mitral valve fibrosis.
Alizzi
Ali M
AM
Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia. alializzi@hotmail.com
Al-Masri
Ayman H
AH
Murton
Mark M
MM
Dixit
Anand S
AS
Hemli
Jonathan M
JM
Challis
Michael
M
Yong
Tuck
T
Nicholson
Michael R
MR
D005260:Female; D005355:Fibrosis; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008784:Methysergide / Q000009:adverse effects*; D008875:Middle Aged; D008943:Mitral Valve / Q000473:pathology; D012702:Serotonin Antagonists / Q000009:adverse effects*
D012702:Serotonin Antagonists; D008784:Methysergide